2 weeks Ago By ABMN Staff
I-Mab ( NASDAQ:IMAB – Get Free Report ) will release its earnings data before the market opens on Thursday, November 14th. Analysts expect I-Mab to post earnings of ($0.16) per share for the quarter.
I-Mab ( NASDAQ:IMAB – Get Free Report ) last announced its quarterly earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.
51) by $0.44. On average, analysts expect I-Mab to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
I-Mab Trading Down 3.5 % Shares of I-Mab stock opened at $1.09 on Thursday.
I-Mab has a fifty-two week low of $0.99 and a fifty-two week high of $2.54.
The stock has a 50 day moving average of $1.20 and a 200 day moving average of $1.44.
Analysts Set New Price Targets Read Our Latest Stock Report on I-Mab I-Mab Company Profile ( Get Free Report ) I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. Featured Stories Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.
com's FREE daily email newsletter ..
